Vantictumab, formerly known as OMP18R5, represents a novel monoclonal antibody designed to specifically target osteopontin receptor 18R5. The therapy is being studied by the company for anticipated applications in https://bookmark-dofollow.com/story28081684/vantictumab-a-deep-dive-into-this-engineered-immune-agent